{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:39:03Z","timestamp":1777865943257,"version":"3.51.4"},"reference-count":23,"publisher":"IMR Press","issue":"1-4","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmazie"],"abstract":"<jats:p>Background: Dexamethasone is typically included in the anti-emetic regimens during the administration of anticancer drugs. However, the incidence and severity of nausea and vomiting in patients receiving anticancer therapy, for whom dexamethasone must be avoided to prevent the recurrence of diabetes mellitus or hepatitis, remain unknown. Methods: This retrospective, observational study evaluated nausea and vomiting in patients with breast cancer who underwent highly emetogenic chemotherapy, including anthracycline and cyclophosphamide, for breast cancer. In all patients, dexamethasone was completely omitted from the standard antiemetic regimen for reasons such as hepatitis, and only palonosetron and aprepitant were administered. Results: For the 82 evaluated cases, the incidence of nausea was 84.1%, vomiting was 14.6%, and the complete response (CR) rate was 8.5%. In addition, the incidence rate of grade 2 or higher nausea (CTCAE ver. 4) was 47.6%, and the proportion of cases in which anticancer drug doses were reduced in the subsequent course due to nausea and vomiting was 2.4%. Factor analysis showed that treatment regimens, age, drinking history, history of prior chemotherapy, and reasons for omitting dexamethasone had no significant effects on the incidence of chemotherapy-induced nausea and vomiting. Conclusions: This study confirmed that the antiemetic effect of only administering palonosetron and aprepitant is insufficient for patients receiving highly emetogenic chemotherapy in whom dexamethasone cannot be administered. Prophylactic administration of other antiemetic drugs is necessary to effectively manage nausea and vomiting in patients receiving anticancer therapy who cannot receive dexamethasone.<\/jats:p>","DOI":"10.31083\/pharmazie51804","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:43:54Z","timestamp":1777535034000},"source":"Crossref","is-referenced-by-count":0,"title":["Antiemetic Efficacy of Dexamethasone Omission in Antiemetic Therapy During Highly Emetogenic Chemotherapy for Breast Cancer"],"prefix":"10.31083","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9517-7283","authenticated-orcid":true,"given":"Wataru","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4682-4369","authenticated-orcid":true,"given":"Kenichi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 192-0392 Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9988-128X","authenticated-orcid":true,"given":"Takashi","family":"Yokokawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9615-0489","authenticated-orcid":true,"given":"Kazuo","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Aoyama","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahito","family":"Sugisaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5914-504X","authenticated-orcid":true,"given":"Masahiro","family":"Hatori","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2023-1300","authenticated-orcid":true,"given":"Kazuyoshi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-5291","authenticated-orcid":true,"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Navari RM. Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs. 2013; 73: 249\u2013262.","DOI":"10.1007\/s40265-013-0019-1"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Chirivella I, Bermejo B, Insa A, P\u00e9rez-Fidalgo A, Magro A, Rosello S, et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Research and Treatment. 2009; 114: 479\u2013484.","DOI":"10.1007\/s10549-008-0018-1"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Sasaki H, Tamura K, Naito Y, Ogata K, Mogi A, Tanaka T, et al. Patient perceptions of symptoms and concerns during cancer chemotherapy: \u2018affects my family\u2019 is the most important. International Journal of Clinical Oncology. 2017; 22: 793\u2013800.","DOI":"10.1007\/s10147-017-1117-y"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO Guideline Update. Journal of Clinical Oncology. 2020; 38: 2782\u20132797.","DOI":"10.1200\/JCO.20.01296"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Ito Y, Tsuda T, Minatogawa H, Kano S, Sakamaki K, Ando M, et al. Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy. Journal of Clinical Oncology. 2018; 36: 1000\u20131006.","DOI":"10.1200\/JCO.2017.74.4375"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Sekine I, Segawa Y, Kubota K, Saeki T. Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Science. 2013; 104: 711\u2013717.","DOI":"10.1111\/cas.12146"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Jeong Y, Han HS, Lee HD, Yang J, Jeong J, Choi MK, et al. A Pilot Study Evaluating Steroid-Induced Diabetes after Antiemetic Dexamethasone Therapy in Chemotherapy-Treated Cancer Patients. Cancer Research and Treatment. 2016; 48: 1429\u20131437.","DOI":"10.4143\/crt.2015.464"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Nakamura M, Ishiguro A, Muranaka T, Fukushima H, Yuki S, Ono K, et al. A Prospective Observational Study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO-01). The Oncologist. 2017; 22: 592\u2013600.","DOI":"10.1634\/theoncologist.2016-0308"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali FS, Qiao W, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. Journal for Immunotherapy of Cancer. 2018; 6: 37.","DOI":"10.1186\/s40425-018-0346-6"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Saito Y, Takekuma Y, Takeshita T, Sugawara M. Influence of Dose Reduction of Prophylactic Dexamethasone on Chemotherapy-induced Nausea and Anorexia in Patients Under 55 Years Old Treated With Anthracycline-containing Regimens. Anticancer Research. 2022; 42: 3753\u20133758.","DOI":"10.21873\/anticanres.15865"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology. 2020; 21: 242\u2013249.","DOI":"10.1016\/S1470-2045(19)30678-3"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Collineau B, Gon\u00e7alves A, Domon M, Bruyat D, Bertucci F, de Nonneville A. Toxicity Profiles of Antibody-Drug Conjugates: Synthesis and Graphical Insights to Optimize Patient-Centered Treatment Strategies for HER2-Negative Metastatic Breast Cancer. Cancers. 2025; 17: 2307.","DOI":"10.3390\/cancers17142307"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Schettini F, Nucera S, Pascual T, Mart\u00ednez-S\u00e1ez O, S\u00e1nchez-Bayona R, Conte B, et al. Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis. Cancer Treatment Reviews. 2025; 132: 102865.","DOI":"10.1016\/j.ctrv.2024.102865"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Sakai H, Tsurutani J, Ozaki Y, Ishiguro H, Nozawa K, Yamanaka T, et al. A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B). Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2025; 36: 31\u201342.","DOI":"10.1016\/j.annonc.2024.09.001"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Kosaka Y, Tanino H, Sengoku N, Minatani N, Kikuchi M, Nishimiya H, et al. Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy. Supportive Care in Cancer. 2016; 24: 1405\u20131411.","DOI":"10.1007\/s00520-015-2905-4"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Hara M, Nakashima T, Harashima H, Ryushima Y, Shimizu C, Kodaira M, et al. Efficacy and safety of aprepitant and dexamethasone in the prevention of nausea and vomiting from neoadjuvant or adjuvant anthracyclines and cyclophosphamide combination therapy in patients with breast cancer. Japanese Journal of Pharmaceutical Health Care and Sciences. 2015; 41: 603\u2013611. (In Japanese)","DOI":"10.5649\/jjphcs.41.603"},{"key":"ref17","unstructured":"Adachi S, Iwai M, Usami E, Kimura M, Okada K, Asano H, et al. Evaluation of appropriate dosage of dexamethasone for prevention of doxorubicin-cyclophosphamide-combination-therapy-induced delayed emesis in patients with breast cancer. Journal of Japanese Society of Hospital Pharmacists. 2020; 56: 305\u2013310. (In Japanese)"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Morrow GR, Morrell C. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. The New England Journal of Medicine. 1982; 307: 1476\u20131480.","DOI":"10.1056\/NEJM198212093072402"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Malik IA, Khan WA, Qazilbash M, Ata E, Butt A, Khan MA. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, anddelayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. American Journal of Clinical Oncology. 1995; 18: 170\u2013175.","DOI":"10.1097\/00000421-199504000-00017"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Razavi D, Delvaux N, Farvacques C, De Brier F, Van Heer C, Kaufman L, et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. Journal of Clinical Oncology. 1993; 11: 1384\u20131390.","DOI":"10.1200\/JCO.1993.11.7.1384"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Kinomura M, Iihara H, Fujii H, Hirose C, Endo J, Yanase K, et al. Effect of Mirtazapine for the Prevention of Nausea and Vomiting in Patients With Thoracic Cancer Receiving Platinum-based Chemotherapy. Anticancer Research. 2023; 43: 1301\u20131307.","DOI":"10.21873\/anticanres.16277"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Iihara H, Iwai M, Morita R, Fujita Y, Ohgino K, Ishihara T, et al. Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial. Lung Cancer. 2024; 192: 107801.","DOI":"10.1016\/j.lungcan.2024.107801"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Jung D, Lee KM, Kim WH, Lee JY, Kim TY, Im SA, et al. Longitudinal Association of Poor Sleep Quality With Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer. Psychosomatic Medicine. 2016; 78: 959\u2013965.","DOI":"10.1097\/PSY.0000000000000372"}],"container-title":["Die Pharmazie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/Pharmazie\/81\/1-4\/10.31083\/Pharmazie51804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:44:04Z","timestamp":1777535044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/Pharmazie\/81\/1-4\/10.31083\/Pharmazie51804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":23,"journal-issue":{"issue":"1-4","published-print":{"date-parts":[[2026]]}},"alternative-id":["S0031-7144(26)02764-0"],"URL":"https:\/\/doi.org\/10.31083\/pharmazie51804","relation":{},"ISSN":["0031-7144","3053-691X"],"issn-type":[{"value":"0031-7144","type":"print"},{"value":"3053-691X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"article-number":"51804"}}